Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 21, 2025 05:20 ET | Source: Elixir Medical Corporation

EuroPCR 2025: Najnowsze dane potwierdzają trwały i istotnie niższy odsetek niepożądanych zdarzeń klinicznych przy zastosowaniu bioadaptatora DynamX® firmy Elixir Medical w porównaniu do stentu uwalniającego lek (DES) w okresie trzech lat

Paris, May 21, 2025 (GLOBE NEWSWIRE) -- — Trwały efekt terapeutyczny z istotnie niższym współczynnikiem niepowodzeń leczenia zmiany docelowej (TLF) – 2,7% wobec 7,2% (p=0,030) dla DynamX® w...
May 21, 2025 05:20 ET | Source: Elixir Medical Corporation

EuroPCR 2025: i dati più recenti dimostrano una riduzione duratura e significativa dei tassi di eventi fino a tre anni con il bioadattatore DynamX® di Elixir Medical rispetto allo stent a rilascio di farmaco

Paris, May 21, 2025 (GLOBE NEWSWIRE) -- —Durata sostenuta dell’efficacia del trattamento con tassi di TLF significativamente inferiori (2,7% vs. 7,2%, p=0,030) con DynamX® rispetto al DES— —Tasso...
May 21, 2025 05:20 ET | Source: Elixir Medical Corporation

EuroPCR 2025: Los datos más recientes demuestran que el bioadaptador DynamX® de Elixir Medical ofrece tasas significativamente menores de acontecimientos adversos a lo largo de tres años en comparación con el stent liberador de fármaco

Paris, May 21, 2025 (GLOBE NEWSWIRE) -- —Durabilidad sostenida del efecto del tratamiento y tasas de fracaso de la lesión objetivo significativamente menores (2,7 % frente a 7,2 %, p=0,030) con...
May 21, 2025 05:20 ET | Source: Elixir Medical Corporation

EuroPCR 2025 : Des données récentes démontrent une réduction durable et statistiquement significative des taux d’événements avec le bioadaptateur DynamX® d’Elixir Medical par rapport au stent à élution médicamenteuse (SEM) sur trois ans

Paris, 21 mai 2025 (GLOBE NEWSWIRE) -- —Un effet thérapeutique durable avec des taux de TLF significativement inférieurs (2,7 % contre 7,2 %, p = 0,030) avec DynamX® par rapport au SEM— —Taux de...
May 21, 2025 05:20 ET | Source: Elixir Medical Corporation

EuroPCR 2025: Aktuelle Daten belegen: Die Ereignisraten nach drei Jahren sind beim DynamX® Bioadaptor von Elixir Medical anhaltend signifikant niedriger als bei medikamentenfreisetzenden Stents

Paris, May 21, 2025 (GLOBE NEWSWIRE) -- – Anhaltende Dauerhaftigkeit des Behandlungseffekts bei signifikant niedrigeren TLF-Raten (2,7 % vs. 7,2 %, p = 0,030) bei DynamX® im Vergleich zu DES – –...
May 21, 2025 05:20 ET | Source: Elixir Medical Corporation

EuroPCR 2025: Late-Breaking Data Demonstrate Sustained Significantly Lower Event Rates With Elixir Medical’s DynamX Bioadaptor Over Drug-Eluting Stent Through Three Years

Paris, May 21, 2025 (GLOBE NEWSWIRE) -- —Sustained durability of treatment effect with significantly lower TLF rates (2.7% versus 7.2%, p=0.030) with DynamX® compared to DES— —Significantly lower...
May 06, 2025 03:00 ET | Source: HeartFlow Holding, Inc.

New Analysis Published in Nature Medicine Demonstrates Advantages of Nationwide Coronary CTA Strategy with Heartflow FFRCT in Over 90,000 Patients with Coronary Artery Disease

MOUNTAIN VIEW, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc., the leader in AI technology for coronary artery disease (CAD), today announced two-year data from FISH&CHIPS, a...
April 25, 2025 04:00 ET | Source: Elixir Medical Corporation

Elixir Medical Announces First Use of LithiX Hertz Contact (HC) Intravascular Lithotripsy System (IVL) in Asia Pacific at Cardiac Vascular Sentral Kuala Lumpur (CVSKL), Malaysia

First cases completed by Dr. Tamil Selvan Muthusamy, MD, and Dr. Rosli Mohd Ali, MD, and transmitted live at TCTAP Congress in Seoul, Korea. Novel IVL technology designed to deliver calcium...
April 10, 2025 09:00 ET | Source: Elixir Medical Corporation

Elixir Medical Announces Launch of LithiX Hertz Contact (HC) Intravascular Lithotripsy System (IVL) in Europe

Novel IVL technology designed to deliver calcium fragmentation for treatment of moderate to severely calcified coronary artery lesions without requiring an energy source. IVL technology expands...
February 25, 2025 08:00 ET | Source: HeartFlow Holding, Inc.

Heartflow Unveils Bold New Vision for Management of Coronary Artery Disease

MOUNTAIN VIEW, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc., the global leader in AI technology for coronary artery disease (CAD) management, today introduced its new brand identity...

Next Page keyboard_arrow_right